Neurogene Inc. filings document a clinical-stage biotechnology issuer developing genetic medicines for rare neurological diseases. Recent 8-K reports furnish operating results, corporate presentations, clinical and regulatory updates for NGN-401 in Rett syndrome, and material-event disclosures tied to board appointments and executive compensation arrangements.
The company's proxy materials cover director elections, board committee matters, executive compensation, equity awards, pay-versus-performance disclosure, and stockholder voting procedures. Together, the filings describe Neurogene's governance framework, common-stock compensation practices, and formal disclosures around its gene-therapy pipeline and financial condition.
Neurogene Inc. entered into an underwriting agreement to complete a public offering of its common stock and pre-funded warrants. The company is issuing 3,500,000 shares of common stock at $30.00 per share and pre-funded warrants to purchase up to 666,666 shares at $29.999999 each. Underwriters exercised in full a 30‑day option to buy an additional 624,999 shares at the public offering price, less underwriting discounts and commissions. Net proceeds from the offering, including the exercised option, are expected to be approximately $134.8 million after fees and expenses. The company states that these proceeds, together with existing cash and cash equivalents, should fund operating and capital needs into the first quarter of 2029.
Neurogene Inc. is offering 3,500,000 shares of common stock and, in lieu of shares to certain investors, pre-funded warrants to purchase 666,666 shares. The public offering price is $30.00 per share. Net proceeds are expected to be approximately $117.2 million (or $134.8 million if the underwriters’ option is exercised in full). Delivery is expected on or about July 2, 2026. The prospectus supplement states the company intends to use proceeds to fund clinical development and pre-commercial activities for NGN-401, for working capital and general corporate purposes. Total common shares outstanding immediately after the offering are projected to be 19,115,786 (or 19,740,785 if the option is exercised in full), based on March 31, 2026 outstanding figures.
Neurogene Inc. proposes an offering of shares of common stock and pre-funded warrants to purchase common stock, together with shares issuable upon exercise of those warrants, via a preliminary prospectus supplement dated (subject to completion). The offering will fund continued development and pre-commercial activities for NGN-401 and for working capital.
The prospectus discloses 15,615,786 shares outstanding as of March 31, 2026, historical net tangible book value of $237.8 million ($15.23 per share) and recent Nasdaq closing price of $32.28 on June 29, 2026. Key terms include tradable common stock and non-listed pre-funded warrants exercisable at $0.000001 per share with ownership limitations.
Neurogene Inc. reported updated, positive Phase 1/2 results for NGN-401, its investigational gene therapy for females with Rett syndrome. Across 10 participants, 47 developmental milestones were gained, averaging 4.7 per participant, and 100% improved on the Clinical Global Impression-Improvement scale and gained at least one milestone.
Milestones accumulated in a progressive, developmentally ordered sequence with rapid onset, as median time to first clinical improvement was two months and gains deepened by 95% from 6 to 12 months and 147% from 6 to at least 12 months. No plateau or loss of milestones was seen through up to 30 months of follow-up, and NGN-401 at the 1E15 vg dose remained generally well-tolerated, with only mild or moderate treatment-related adverse events and no new treatment-related serious adverse events. Neurogene has completed dosing of 25 participants in the Embolden registrational trial, which uses a composite responder endpoint, and expects topline data in the second half of 2027.
Neurogene Inc. director Woods Keith received a stock option grant to acquire 15,400 shares of common stock at an exercise price of $32.30 per share. The option was granted as a compensation award and vests in equal monthly installments through January 16, 2027, conditioned on continued service. Following this grant, Woods holds 15,400 stock options expiring on January 16, 2034.
Neurogene Inc. director Keith Woods received a fully vested stock option grant covering 7,700 shares of common stock. The option has an exercise price of $42.59 per share and expires on June 14, 2034. Following this award, he holds 7,700 stock options directly.
Neurogene Inc. director Keith Woods received a fully vested non-qualified stock option grant. The award covers 12,050 options, each giving the right to buy one share of common stock at an exercise price of $20.40 per share, expiring on June 12, 2035. Following this compensation-related grant, Woods holds 12,050 derivative securities directly, with no open-market share purchases or sales reported in this filing.
Neurogene Inc. director Woods Keith filed an amended Form 3, which is the initial statement of beneficial ownership for insiders. This amendment reports no share purchases, sales, option exercises, or other equity transactions, and shows no derivative securities or other holdings disclosed in this filing.
Neurogene Inc. has completed dosing in Embolden, its registrational trial of NGN-401, an investigational one-time gene therapy for Rett syndrome. The company exceeded its initial 20-participant target by dosing 25 patients after strong community demand, with a pre-specified intent-to-treat population of 24 for the primary analysis.
At the 1E15 vg dose, NGN-401 has been generally well-tolerated; as of June 7, 2026, 35 treated participants across trials showed no cases of hemophagocytic lymphohistiocytosis. Interim Phase 1/2 data in 10 participants reported multidomain, durable functional gains, with 35 developmental milestones achieved and 88% improving on the CGI-I scale.
Embolden’s primary endpoint requires a 33% minimum response rate, or 8 of 24 participants, at 12 months to support a planned Biologics License Application. Neurogene expects updated Phase 1/2 data in mid-2026 and topline Embolden results in the second half of 2027.
Neurogene Inc. reported the results of its 2026 annual stockholder meeting. Stockholders representing 11,387,407 common shares, about 72.92% of voting power, were present, establishing a quorum. Two Class III directors, Robert Baffi and Rohan Palekar, were elected to serve until the 2029 annual meeting.
Stockholders approved, on an advisory basis, the compensation of the company’s named executive officers and ratified Deloitte & Touche LLP as independent auditor for the year ending December 31, 2026. In a separate advisory vote, investors expressed a preference for annual advisory votes on executive pay, and the company plans to hold them every year.